

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

DIVISION OF CORPORATION FINANCE

November 8, 2017

Douglas Treco President and Chief Executive Officer Ra Pharmaceuticals, Inc. 87 Cambridge Park Drive Cambridge, MA 02140

> Re: Ra Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed November 1, 2017 File No. 333-221266

Dear Dr. Treco:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jeffrey Gabor at 202-551-2544 with any questions.

Division of Corporation Finance Office of Healthcare & Insurance

cc: Robert Puopolo